Boehringer Ingelheim has become the latest pharma company to investigate KRAS as a potential target for cancer drugs, striking a multi-year oncology research deal with the University of Tex
Sandoz is to appeal a court decision preventing it from launching a cheaper biosimilar competitor to Amgen’s Enbrel (etanercept) inflammatory diseases drug in the US, three years after appr
Amgen has lived up to its litigious reputation after it successfully persuaded a German court to uphold a patent blocking Sanofi from marketing its rival injected cholesterol drug in the co
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
